drugset / Trial / NCT00957944

Study in Healthy Volunteers to Prove That Two Rotigotine Patches From Different Manufacturing Sites Deliver Equivalent Drug Amount to the Body

NCT00957944

Phase 1 Completed 40 enrolled UCB Pharma
RandomizedCrossoverOpen-labelBasic science

Summary

The major aim of this study is to investigate and compare the drug amount delivered to the body after sequential application of 2 rotigotine transdermal patches from 2 different manufacturing sites.

Timeline

Start
2009-07
Primary completion
2009-08
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Rotigotine Unknown 4.5 mg Other

Indications

No indication recorded.